CD8A and neoplasm: To understand the duration of immune response in the tumors of non-RFA side in RFA group, we measured the tumor-infiltrating CD8+PD-1+ T cells of non-RFA side on days 3, 5, and 8 after RFA treatment by flow cytometry.